Supreme Court Shuns Pfizer Appeal in Neurontin Cases

, The Litigation Daily


The high court declined on Monday to take up Pfizer Inc.'s challenge to a $142 million jury verdict and continued litigation stemming from the company's off-label marketing of the epilepsy drug Neurontin.

This premium content is reserved for American Lawyer subscribers.

Continue reading by getting started with a subscription.

Already a subscriber? Log in now

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202631590695

Thank you!

This article's comments will be reviewed.